Tag Archives: Joseph Pantginis

H.C. Wainwright Maintains Their Buy Rating on Beyondspring Inc (BYSI)

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Beyondspring Inc (BYSI – Research Report), with a price target of $41. The company’s shares closed last Monday at $19.14. Pantginis said: “Valuation and risks

Cytokinetics Inc (CYTK) Received its Third Buy in a Row

After Cantor Fitzgerald and JMP Securities gave Cytokinetics Inc (NASDAQ: CYTK) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Joseph Pantginis reiterated a Buy rating on Cytokinetics Inc today and set a

What Made H.C. Wainwright Downgrade Fibrocell Science Inc’s Stock?

Fibrocell Science Inc (FCSC – Research Report) received a Hold rating and a $3 price target from H.C. Wainwright analyst Joseph Pantginis today. The company’s shares closed last Monday at $2.93. Pantginis commented: “Valuation and risks to price target achievement.

H.C. Wainwright Sticks to Its Buy Rating for Oxford BioMedica plc (OXBDF)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Oxford BioMedica plc (OXBDF – Research Report), with a price target of $14.50. The company’s shares closed last Monday at $7.80, close to its 52-week

Kura Oncology (KURA) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Kura Oncology (KURA – Research Report) today and set a price target of $29. The company’s shares closed last Monday at $15.12. Pantginis said: “Valuation and impediments to achieving price

Analysts Offer Insights on Healthcare Companies: Mustang Bio Inc (NASDAQ: MBIO), CareDx (NASDAQ: CDNA) and Spectrum Pharmaceuticals (NASDAQ: SPPI)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mustang Bio Inc (MBIO – Research Report), CareDx (CDNA – Research Report) and Spectrum Pharmaceuticals (SPPI – Research Report) with bullish sentiments.